Ratings Cronos Group Inc. Nasdaq

Equities

CRON

CA22717L1013

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.59 ^USD	+3.60%		+9.28%	+23.92%

Apr. 02	Cannabis Stocks: Wedbush Notes Florida Supreme Court Approved Proposed Amendment For Adult Use Cannabis to be Placed on the 2024 General Election Ballot	MT
Mar. 25	Cronos Group Brief: Launching 'Lord Jones' Chocolate Fusions	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
Thanks to a sound financial situation, the firm has significant leeway for investment.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
CRONOS GROUP INC.	+23.92%	985M		-
DONG-E-E-JIAO CO.,LTD.	+35.04%	5.92B		B-
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-15.13%	4.51B		C+
TASLY PHARMACEUTICAL GROUP CO., LTD	-9.75%	3.15B		B-
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+2.14%	3.1B		C
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-6.82%	2.42B	-	D+
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+47.87%	1.97B		-
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-7.89%	1.68B	-	-
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	+0.09%	1.65B	-	-
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-12.97%	1.53B		C-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes